Enliven Therapeutics, Inc. (ELVN)
| Market Cap | 2.57B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -103.69M |
| Shares Out | 59.80M |
| EPS (ttm) | -1.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 618,956 |
| Open | 45.31 |
| Previous Close | 44.90 |
| Day's Range | 42.81 - 45.31 |
| 52-Week Range | 14.79 - 48.53 |
| Beta | 0.49 |
| Analysts | Strong Buy |
| Price Target | 43.40 (+1.1%) |
| Earnings Date | May 13, 2026 |
About ELVN
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and othe... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ELVN stock is "Strong Buy." The 12-month stock price target is $43.4, which is an increase of 1.10% from the latest price.
News
Enliven Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
ELVN-001 is advancing to phase 3 for CML, showing strong efficacy and safety in heavily pretreated patients. The company is well-funded, targeting a $9B US market, and plans to present updated data in June, with regulatory milestones expected by year-end.
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
BOULDER, Colo., Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of...
Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars
Enliven Therapeutics Inc. (NASDAQ: ELVN) stock is trading higher on Thursday, with a session volume of 6.61 million compared to the average volume of 631.52 thousand as per data from Benzinga Pro.
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts ELVN-001 continues to demonstrate a favorable s...
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
Scott Garland, a seasoned biopharma executive with a strong track record of leading successful companies and drug launches, joins Enliven's Board of Directors Building on positive data reported in 202...
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
BOULDER, Colo., Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. ("Enliven"), (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molec...
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive Officer Co-Founder Sam Kintz will assume a new position as Hea...
Enliven Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Focused on a selective ATP-competitive BCR-ABL inhibitor for CML, the team reports promising early efficacy in heavily pretreated patients and plans a large phase III trial next year. Rising resistance to allosteric TKIs and evolving treatment dynamics support their differentiated approach.
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML Remains on track to initiate Phase 3 pivotal trial of ELVN-001 in 2026 Strong balance sheet with ...
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting
BOULDER, Colo. , Aug. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development o...
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks and demonstrating a favorable safety a...
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
BOULDER, Colo. , June 16, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development o...
Enliven Therapeutics Transcript: Study Update
ELVN-001 demonstrated robust efficacy and favorable safety in heavily pretreated CML patients, with 47% achieving MMR by 24 weeks and low discontinuation rates. The drug's selectivity, convenient dosing, and strong safety profile support its advancement to pivotal trials targeting a broad CML population.
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
BOULDER, Colo. , June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development o...
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BOULDER, Colo. , June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development o...
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress
Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::...
Enliven Therapeutics Transcript: Jefferies Global Healthcare Conference 2025
A late-line CML therapy shows promising efficacy and safety, with a pivotal study planned and a focus on optimal dosing. The company is considering a broader second line plus trial for greater commercial impact and maintains a strong cash position into late 2027.
Enliven Therapeutics Transcript: TD Cowen's 6th Annual Oncology Innovation Summit
ELVN-001 continues to show strong efficacy and tolerability in heavily pretreated CML patients, with upcoming EHA data expected to further validate its profile. Plans are underway for pivotal trials targeting both late- and earlier-line settings, while resources are being focused on ELVN-001 over ELVN-002.
Enliven Therapeutics to Present at Upcoming Investor Conferences
BOULDER, Colo., May 22, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of ...
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June EHA abstract reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26%...
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress
Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::A...
Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting
BOULDER, Colo. , April 2, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development o...
Final Trade: CVX, XLE, ELVN, COF
The final trades of the day with the Fast Money traders.
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials in second half of 2025 Strong b...
Enliven Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference
The company is advancing two clinical-stage oncology assets, with ELVN-001 showing strong efficacy and safety in late-line CML and a major data update expected mid-2024. Plans are in place for a pivotal phase III trial, while strategic alternatives are being considered for ELVN-002.